Onco Actu du 3 septembre 2018

	5.1 Traitements - Pré-clinique
How tiny metal beads could make chemotherapy more effective for brain tumours [Cancer Research UK] They’re tweaking the drug so that it’s inactive when given to the patient. That’s until the drug reaches the implant: tiny beads made from the metal palladium. These would be placed inside the brain around the area where the tumour was removed during surgery. When the drug encounters the metal, it gets switched on in the perfect place to potentially kill any cancerous cells that might be left in the brain.
	5.10 Traitements - Essais
Understanding and predicting deception in clinical trials [Stanford Medicine ] In a literature review of 90 papers, they identified 103 instances of participant dishonesty. In those trials, between 3 to 25 percent of healthy participants were practicing some form of deceit.
	5.2 Pharma
Lilly hands its oncology baton—and big ambitions—to R&D executive Anne White [FiercePharma] White will draw on that experience to keep the Verzenio launch rolling and pump up other recent launches, too. Lilly is counting on drugs Cyramza and Lartruvo, in addition to the breast-cancer fighter, to help it meet 2018 sales forecasts of $23 billion to $23.5 billion.
Anne White Promoted to President of Lilly Oncology [Lilly] White joined Lilly in 1991 as an engineer before transitioning to clinical research and later oncology drug development both in and outside the company. White holds a bachelor's degree in engineering from the University of Michigan.
	5.2.2 Pharma - Fusions & Acquisitions
Shire completes sale of oncology franchise to Servier [Pharma Times] Shire’s oncology business includes in-market products Oncaspar (pegaspargase), a component of multi-agent treatment for acute lymphoblastic leukemia (ALL), and ex-US rights to Onivyde (irinotecan pegylated liposomal formulation), which is part of a treatment regimen for metastatic pancreatic cancer post gemcitabine-based therapy.
	5.2.3 Pharma - économie
Can Amgen's new-and-improved Kyprolis kick-start myeloma sales? [FiercePharma] Not all of Kyprolis’ recent clinical trial performances have been as sunny, however. In 2016, the drug’s growth prospects took a hit when a combination of Kyprolis, melphalan and prednisone failed to top a cocktail of melphalan, prednisone and Johnson & Johnson and Takeda’s Velcade at improving survival among previously untreated patients.
	6.5 Médecines alternatives/complémentaires
Bad Documentary Review: Cancer Can Be Killed [Science-Based Medicine] You can view dozens of documentaries free of charge with Amazon Prime that support anti-vaccine views, peddle unproven cancer therapies, and all other sorts of nonsense. Which brings me to a documentary called Cancer Can Be Killed. Cancer Can Be Killed was produced by Jeff Witzeman and released in the summer of 2017.
Helene Langevin is named NCCIH director. Let the quackery flow again! [Respectful Insolence] She is a quackademic in every sense of the word. That’s why I think the balance of power at NCCIH is about to shift back more towards pseudoscience and quackery than it’s been since the late 1990s. Worse, Dr. Langevin will have the largest budget ever at NCCIH to fund that shift.
	6.6 Publications
Mapping Open Science Tools [The Scholarly Kitchen] In this review of scholarly tools, I evaluated the discipline specialty or neutrality in open science workflow solutions. I was surprised to see that 100% of open science tools for the outreach and promotional phase aim to be discipline agnostic. Whereas, data analysis and publication tools favor STM research.
	6.7 DMP, Big Data & applis
Georgetown Releases Updated Database for Genomic, Clinical Research on Brain Cancer [Genome Web] Bioinformaticians at Georgetown University Medical Center are expecting to see an uptick in genome-based research into brain cancers — even with data that is more than a decade old — thanks to the public release of an enhanced version of a dataset formerly hosted by the National Cancer Institute.
	6.7.1 IA/bioinformatique
AI can predict how cancers will progress, scientists find [The Telegraph] "We've developed a powerful artificial intelligence tool which can make predictions about the future steps in the evolution of tumours based on certain patterns of mutation that have so far remained hidden within complex data sets."
	6.9 Controverses
Is Big Pharma really more evil than academia? [The Guardian] The pharmaceutical industry gets a bad press. Some of the criticism is surely deserved, but the widespread notion that academia is morally superior is ridiculous.